Immunotherapy after standard treatment may extend lives in lung cancer
NCT ID NCT03540420
First seen Apr 18, 2026 · Last updated Apr 28, 2026 · Updated 1 time
Summary
This study tests whether adding the immunotherapy drug atezolizumab after standard chemo-radiotherapy helps people with limited-stage small-cell lung cancer live longer. About 212 participants will receive either atezolizumab or no additional treatment. The goal is to see if this approach improves 2-year survival and delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aalborg Universitetshospital
Aalborg, Denmark
-
Akershus Universitetssykehus AHUS
Oslo, Norway
-
Amphia Ziekenhuis
Breda, Netherlands
-
Antoni van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands
-
Antonius Ziekenhuis
Utrecht, Netherlands
-
Cancer Clinic at St. Olavs Hospital
Trondheim, Norway
-
Cantonal Hospital of St. Gallen
Sankt Gallen, Switzerland
-
Drammen sykehus - Vestre Viken
Drammen, Norway
-
Erasmus MC
Rotterdam, Netherlands
-
Gävle hospital
Gävle, Sweden
-
Haugesund hospital
Haugesund, Norway
-
Haukeland Universitetssykehus
Bergen, Norway
-
Hirslanden Klinik
Zurich, Switzerland
-
Inselspital
Bern, Switzerland
-
Isala Ziekenhuis
Zwolle, Netherlands
-
Kantonsspital Graubünden
Chur, Switzerland
-
Kantonsspital Olten - Solothurner Spitäler
Olten, Switzerland
-
Kantonsspital Winterthur
Winterthur, Switzerland
-
Karolinska University Hospital
Stockholm, Sweden
-
Medische Centrum Twente
Enschede, Netherlands
-
Molde Sjukehus
Molde, Norway
-
National Cancer Institute
Vilnius, Lithuania
-
Odense University Hospital
Odense, Denmark
-
Oslo University Hospital Ullevål
Oslo, Norway
-
Rigshospitalet
Copenhagen, Denmark
-
Rijnstate Ziekenhuis
Arnhem, Netherlands
-
Sahlgrenska Universitetssjukhus
Gothenburg, Sweden
-
Skånes University Hospital
Lund, Sweden
-
Spital STS AG
Thun, Switzerland
-
Stavanger University Hospital
Stavanger, Norway
-
Sykehuset Levanger
Levanger, Norway
-
Sykehuset i Kristansund
Kristiansund, Norway
-
Sørlandet Sykehus
Kristiansand, Norway
-
Universitetssjukhuset Linköping
Linköping, Sweden
-
Universitetssjukhuset Örebro
Örebro, Sweden
-
Universitetssykehuset Nord-Norge
Tromsø, Norway
-
University Hospital Inselspital
Bern, Switzerland
-
Universitätsspital Basel
Basel, Switzerland
-
Volda hospital
Volda, Norway
-
Zuyderland Ziekenhuis
Sittard, Netherlands
-
Ålesund Hospital
Ålesund, Norway
Conditions
Explore the condition pages connected to this study.